Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2022 –2029 | |
|
|
USD 62.00 Billion |
| USD 110.58 Billion | |
| % | |
|
Global Metabolic Disorders Therapeutics Market, By Therapy Type (Enzyme Replacement Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy, Others), Application (Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
The metabolic disorders therapeutics market is projected to witness major growth during the forecast period. Increasing cases of hypertension, cardiomyopathy, diabetes and hypercholesterolemia boost the metabolic syndrome market. Factors such as adaptation of unhealthy lifestyle, increased stress in daily life & malnutrition and family history with cardiac disease are also increasing the market growth. Many major market players are contributing a lot in drug discovery and development. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the metabolic disorders therapeutics market in the forecast period 2022-2029. The expected CAGR of metabolic disorders therapeutics market is tend to be around 7.50% in the mentioned forecast period. The market was valued at USD 62 billion in 2021, and it would grow upto USD 110.58 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Therapy Type (Enzyme Replacement Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy, Others), Application (Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Atkins Global (U.S.), Herbalife International of America Inc., (U.S.), Nutrisystem Inc., (U.S.), Abbott (U.S.), Kellogg Co. (U.S.), mega Laboratories, Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Medtronic (Ireland.), Apollo Endosurgery Inc., (U.S.), GSK plc (U.K), Olympus Corporation (India), WW International Inc., (U.S.), Jenny Craig (U.S.), Gold’s Gym (U.S.), DSM (Netherlands), Brunswick (U.S.), Amer Sports (Finland), Johnson Health Tech (U.S.), Technogym SpA (Italy), Shaklee Corporation (U.S.), Nature's Sunshine Products, Inc., (U.S.) and Novo Nordisk A/S (Denmark)
|
|
Market Opportunities
|
|
Market Definition
Metabolic syndrome is the condition of grouped diseases that occur together and increases the risk of heart disease, stroke and type 2 diabetes. These conditions involve high blood sugar, abnormal cholesterol level, increased blood pressure, excess body fat around the waist, increased blood pressure. Having one of the diseases doesn’t mean patient suffering from metabolic syndrome but, having two to three diseases at the same time increases the risk of metabolic syndrome. Symptom involves increased thirst & urination, blurred vision and fatigue. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Drivers
Increasing awareness among patients and several healthcare professionals for the treatment of different types of metabolic syndromes and more and more usage of combination therapy are the major factors that are expected to boost the demand for global metabolic syndrome market during the forecast period of 2022-2029.
The global metabolic syndrome market is projected to be driven by the rising R&D investments in drug discovery and development and the increasing prevalence of diabetes. For instance, as per the reports of International Diabetes Federation, for the treatment of diabetes as a metabolic syndrome, about 415 million people are currently affected by diabetes worldwide and it is hoped to increase to 642 million diabetic people by the year 2040.
Opportunities
Increase in the number of metabolic syndromes therapeutics being delivered through retail pharmacies and rise in the number of retail pharmacies in highly developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
The drug therapy is driving the market because of its extensive usage as a result if ease of administration and high-reliability rate. This therapy is anticipated to maintain its growth even due to its advanced ways of administering medicines without disturbing daily patient lives. Furthermore, the launch of smart drug delivery devices and smart dosage control methods are projected to boost the segment further.
Restraints/Challenges
Lack of trained healthcare professionals who are unaware of the knowledge of the treatment methods for this disease could reduce the growth of the global metabolic disorders therapeutics market over a forecast period.
The huge expenditure of the treatment methods hamper the market growth.
This global metabolic disorders therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global metabolic disorders therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
The Covid-19 pandemic let a negative impact on the global metabolic disorders therapeutics market because the utmost priority was given to Covid-19 patients for treatment. Numerous medical colleges and hospitals were reorganised and helped in the structure so that they can accommodate more patients diagnosed with Covid-19. Discovery and development of drugs for the types of metabolic syndromes also slowed down during the pandemic, but it wasn’t in a pause and now in the post pandemic era, it is growing again.
The global metabolic disorders therapeutics market is segmented on the basis of therapy type, application, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Therapy Type
Application
End-Users
Distribution Channel
The global metabolic disorders therapeutics market is analysed and market size insights and trends are provided by therapy type, application, distribution channel and end-user as referenced above.
The major countries covered in the global metabolic disorders therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to increased geriatric population, and presence of key manufacture of the product.
Asia-Pacific dominates the market due to increased prevalence of coronary heart diseases and related disorders, increased awareness programmes on the healthy lifestyle and number of generic drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The global metabolic disorders therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global metabolic disorders therapeutics market.
Key players operating in the global metabolic disorders therapeutics market include:
SKU-
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY BASED MODELLING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES MODEL
5.3 STRATEGIC INITIATIVES
6 EPIDEMIOLOGY
6.1 DISEASE PREVALENCE BY COUNTRY
6.2 DISEASE INCIDENCE BY COUNTRY
6.3 RISK FACTORS
(FACTORS THAT INCREASE THE LIKELIHOOD OF DEVELOPING A DISEASE, SUCH AS AGE, GENDER, LIFESTYLE FACTORS, ENVIRONMENTAL EXPOSURES, AND GENETIC PREDISPOSITION)
6.4 HEALTHCARE UTILIZATION
(HOW THE DISEASE AFFECTS HEALTHCARE UTILIZATION, SUCH AS HOSPITALIZATIONS, EMERGENCY ROOM VISITS, AND OUTPATIENT VISITS)
7 REGULATORY FRAMEWORK
7.1 REGULATORY APPROVAL PROCESS
7.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
7.3 REGULATORY APPROVAL PATHWAYS
7.4 LICENSING AND REGISTRATION
7.5 POST-MARKETING SURVEILLANCE
7.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
8 PIPELINE ANALYSIS
8.1 CLINICAL TRIAL STATUS
8.1.1 CANDIDATE/AGENT
8.1.2 PROPERTIES
8.1.3 COMPANY NAME
8.1.4 THERAPEUTIC AREA
8.1.5 PRODUCT NAME
8.1.6 GENERIC NAME
8.1.7 TYPE
8.1.8 RESEARCH CODE
8.1.9 INDICATION
8.1.10 ORIGINATOR
8.1.11 SPONSOR
8.1.12 COLLABORATOR
8.1.13 LICENSOR
8.1.14 LICENSEE
8.2 DISTRIBUTION OF PRODUCTS BY PHASE
8.2.1 PRECLINICAL/RESEARCH PROJECT
8.2.2 PHASE I
8.2.3 PHASE II
8.2.4 PHASE III
8.2.5 PHSE IV
8.3 NUMBER OF SUBJECTS IN CLINICAL TRIALS
8.3.1 PHASE I
8.3.2 PHASE II
8.3.3 PHASE III
8.4 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
8.4.1 PRECLINICAL/RESEARCH PROJECT
8.4.2 PHASE I
8.4.3 PHASE II
8.4.4 PHASE III
8.4.5 PHASE IV
8.5 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
8.5.1 PRECLINICAL/RESEARCH PROJECT
8.5.2 PHASE I
8.5.3 PHASE II
8.5.4 PHASE III
8.5.5 PHASE IV
8.6 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
8.6.1 PRECLINICAL/RESEARCH PROJECT
8.6.2 PHASE I
8.6.3 PHASE II
8.6.4 PHASE III
8.6.5 PHASE IV
9 MARKETED DRUG ANALYSIS
9.1 DRUG
9.1.1 BRAND NAME
9.1.2 GENERICS NAME
9.2 THERAPEUTIC INDIACTION
9.3 PHARACOLOGICAL CLASS OD THE DRUG
9.4 DRUG PRIMARY INDICATION
9.5 MARKET STATUS
9.6 MEDICATION TYPE
9.7 DRUG DOSAGES FORM
9.8 DOSAGES AVAILABILITY
9.9 PACKAGING TYPE
9.1 DRUG ROUTE OF ADMINISTRATION
9.11 DOSING FREQUENCY
9.12 DRUG INSIGHT
AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
9.12.1 FORECAST MARKET OUTLOOK
9.12.2 CROSS COMPETITION
9.12.3 THERAPEUTIC PORTFOLIO
9.12.4 CURRENT DEVELOPMENT SCENARIO
10 MARKET ACCESS
10.1 10-YEAR MARKET FORECAST
10.2 CLINICAL TRIAL RECENT UPDATES
10.3 ANNUAL NEW FDA APPROVED DRUGS
10.4 DRUGS MANUFACTURER AND DEALS
10.5 MAJOR DRUG UPTAKE
10.6 CURRENT TREATMENT PRACTICES
10.7 IMPACT OF UPCOMING THERAPY
11 R & D ANALYSIS
11.1 COMPARATIVE ANALYSIS
11.2 DRUG DEVELOPMENTAL LANDSCAPE
11.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
11.4 THERAPEUTIC ASSESSMENT
11.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
12 PATENT ANALYSIS
12.1 PATENT LANDSCAPE
12.2 USPTO NUMBER
12.3 PATENT EXPIRY
12.3.1 US PATENT EXPIRY
12.3.2 EUROPE PATENT EXPIRY
12.4 EPIO NUMBER
12.5 PATENT STRENGTH AND QUALITY
12.6 PATENT CLAIMS
12.7 PATENT CITATIONS
12.8 PATENT LITIGATION AND LICENSING
12.9 FILE OF PATENT
12.1 PATENT RECEIVED CONTRIES
12.11 TECHNOLOGY BACKGROUND
13 COMPETITIVE INTELLIGENCE TRACKING DATA
13.1 CLINICAL TRIAL MONITORING ANALYSIS
13.2 REGULATORY AND COMMERCIAL MONITORING ANALYSIS
14 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY THERAPY TYPE
(NOTE: MARKET VALUE, MARKET VOLUME AND ASP WILL BE PROVIDED FOR ALL SEGMENTS AND SUB-SEGMENTS )
14.1 OVERVIEW
14.2 ENZYME REPLACEMENT THERAPY
14.2.1 IMIGLUCERASE
14.2.1.1. MARKET VALUE (USD MILLION)
14.2.1.2. MARKET VOLUME (UNITS)
14.2.1.3. AVERAGE SELLING PRICE (USD)
14.2.2 VELAGLUCERASE ALFA
14.2.2.1. MARKET VALUE (USD MILLION)
14.2.2.2. MARKET VOLUME (UNITS)
14.2.2.3. AVERAGE SELLING PRICE (USD)
14.2.3 TALIGLUCERASE ALFA
14.2.3.1. MARKET VALUE (USD MILLION)
14.2.3.2. MARKET VOLUME (UNITS)
14.2.3.3. AVERAGE SELLING PRICE (USD)
14.2.4 AGALSIDASE ALFA
14.2.4.1. MARKET VALUE (USD MILLION)
14.2.4.2. MARKET VOLUME (UNITS)
14.2.4.3. AVERAGE SELLING PRICE (USD)
14.2.5 AGALSIDASE BETA
14.2.5.1. MARKET VALUE (USD MILLION)
14.2.5.2. MARKET VOLUME (UNITS)
14.2.5.3. AVERAGE SELLING PRICE (USD)
14.2.6 ALGLUCOSIDASE ALFA
14.2.6.1. MARKET VALUE (USD MILLION)
14.2.6.2. MARKET VOLUME (UNITS)
14.2.6.3. AVERAGE SELLING PRICE (USD)
14.2.7 IDURSULFASE
14.2.7.1. MARKET VALUE (USD MILLION)
14.2.7.2. MARKET VOLUME (UNITS)
14.2.7.3. AVERAGE SELLING PRICE (USD)
14.2.8 GALSULFASE
14.2.8.1. MARKET VALUE (USD MILLION)
14.2.8.2. MARKET VOLUME (UNITS)
14.2.8.3. AVERAGE SELLING PRICE (USD)
14.2.9 ALDURAZYME
14.2.9.1. MARKET VALUE (USD MILLION)
14.2.9.2. MARKET VOLUME (UNITS)
14.2.9.3. AVERAGE SELLING PRICE (USD)
14.2.10 BETAINE
14.2.10.1. MARKET VALUE (USD MILLION)
14.2.10.2. MARKET VOLUME (UNITS)
14.2.10.3. AVERAGE SELLING PRICE (USD)
14.2.11 CYSTEAMINE
14.2.11.1. MARKET VALUE (USD MILLION)
14.2.11.2. MARKET VOLUME (UNITS)
14.2.11.3. AVERAGE SELLING PRICE (USD)
14.2.12 LARONIDASE
14.2.12.1. MARKET VALUE (USD MILLION)
14.2.12.2. MARKET VOLUME (UNITS)
14.2.12.3. AVERAGE SELLING PRICE (USD)
14.2.13 IDURSULFASE
14.2.13.1. MARKET VALUE (USD MILLION)
14.2.13.2. MARKET VOLUME (UNITS)
14.2.13.3. AVERAGE SELLING PRICE (USD)
14.2.14 GALSULFASE
14.2.14.1. MARKET VALUE (USD MILLION)
14.2.14.2. MARKET VOLUME (UNITS)
14.2.14.3. AVERAGE SELLING PRICE (USD)
14.2.15 ALDURAZYME
14.2.15.1. MARKET VALUE (USD MILLION)
14.2.15.2. MARKET VOLUME (UNITS)
14.2.15.3. AVERAGE SELLING PRICE (USD)
14.2.16 OTHER
14.3 GENE THERAPY
14.3.1 STRIMVELIS
14.3.1.1. MARKET VALUE (USD MILLION)
14.3.1.2. MARKET VOLUME (UNITS)
14.3.1.3. AVERAGE SELLING PRICE (USD)
14.3.2 VALOCTOCOGENE ROXAPARVOVEC
14.3.2.1. MARKET VALUE (USD MILLION)
14.3.2.2. MARKET VOLUME (UNITS)
14.3.2.3. AVERAGE SELLING PRICE (USD)
14.3.3 ETRANACOGENE DEZAPARVOVEC
14.3.3.1. MARKET VALUE (USD MILLION)
14.3.3.2. MARKET VOLUME (UNITS)
14.3.3.3. AVERAGE SELLING PRICE (USD)
14.3.4 VOLANESORSEN
14.3.4.1. MARKET VALUE (USD MILLION)
14.3.4.2. MARKET VOLUME (UNITS)
14.3.4.3. AVERAGE SELLING PRICE (USD)
14.3.5 PEGVALIASE
14.3.5.1. MARKET VALUE (USD MILLION)
14.3.5.2. MARKET VOLUME (UNITS)
14.3.5.3. AVERAGE SELLING PRICE (USD)
14.3.6 OTHER
14.4 SMALL MOLECULE-BASED THERAPY
14.4.1 METFORMIN
14.4.1.1. MARKET VALUE (USD MILLION)
14.4.1.2. MARKET VOLUME (UNITS)
14.4.1.3. AVERAGE SELLING PRICE (USD)
14.4.2 SULFONYLUREAS
14.4.2.1. MARKET VALUE (USD MILLION)
14.4.2.2. MARKET VOLUME (UNITS)
14.4.2.3. AVERAGE SELLING PRICE (USD)
14.4.3 DPP-4 INHIBITORS
14.4.3.1. SITAGLIPTIN
14.4.3.1.1. MARKET VALUE (USD MILLION)
14.4.3.1.2. MARKET VOLUME (UNITS)
14.4.3.1.3. AVERAGE SELLING PRICE (USD)
14.4.3.2. SAXAGLIPTIN
14.4.3.2.1. MARKET VALUE (USD MILLION)
14.4.3.2.2. MARKET VOLUME (UNITS)
14.4.3.2.3. AVERAGE SELLING PRICE (USD)
14.4.4 SGLT2 INHIBITORS
14.4.4.1. CANAGLIFLOZIN
14.4.4.1.1. MARKET VALUE (USD MILLION)
14.4.4.1.2. MARKET VOLUME (UNITS)
14.4.4.1.3. AVERAGE SELLING PRICE (USD)
14.4.4.2. EMPAGLIFLOZIN
14.4.4.2.1. MARKET VALUE (USD MILLION)
14.4.4.2.2. MARKET VOLUME (UNITS)
14.4.4.2.3. AVERAGE SELLING PRICE (USD)
14.4.5 EZETIMIBE
14.4.5.1. MARKET VALUE (USD MILLION)
14.4.5.2. MARKET VOLUME (UNITS)
14.4.5.3. AVERAGE SELLING PRICE (USD)
14.4.6 TETRAHYDROBIOPTERIN
14.4.6.1. MARKET VALUE (USD MILLION)
14.4.6.2. MARKET VOLUME (UNITS)
14.4.6.3. AVERAGE SELLING PRICE (USD)
14.4.7 D-PENICILLAMINE
14.4.7.1. MARKET VALUE (USD MILLION)
14.4.7.2. MARKET VOLUME (UNITS)
14.4.7.3. AVERAGE SELLING PRICE (USD)
14.4.8 TRIENTINE
14.4.8.1. MARKET VALUE (USD MILLION)
14.4.8.2. MARKET VOLUME (UNITS)
14.4.8.3. AVERAGE SELLING PRICE (USD)
14.4.9 OTHER
14.5 SUBSTRATE REDUCTION THERAPY
14.5.1 ZAVESCA
14.5.1.1. MARKET VALUE (USD MILLION)
14.5.1.2. MARKET VOLUME (UNITS)
14.5.1.3. AVERAGE SELLING PRICE (USD)
14.5.2 GALAFOLD
14.5.2.1. MARKET VALUE (USD MILLION)
14.5.2.2. MARKET VOLUME (UNITS)
14.5.2.3. AVERAGE SELLING PRICE (USD)
14.5.3 OTHER
14.6 CELLULAR TRANSPLANTATION
14.6.1 HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
14.6.1.1. MARKET VALUE (USD MILLION)
14.6.1.2. MARKET VOLUME (UNITS)
14.6.1.3. AVERAGE SELLING PRICE (USD)
14.6.2 ISLET CELL TRANSPLANTATION
14.6.2.1. MARKET VALUE (USD MILLION)
14.6.2.2. MARKET VOLUME (UNITS)
14.6.2.3. AVERAGE SELLING PRICE (USD)
14.6.3 PANCREATIC ISLET CELL ENCAPSULATION
14.6.3.1. MARKET VALUE (USD MILLION)
14.6.3.2. MARKET VOLUME (UNITS)
14.6.3.3. AVERAGE SELLING PRICE (USD)
14.6.4 NEURAL STEM CELL TRANSPLANTATION
14.6.4.1. MARKET VALUE (USD MILLION)
14.6.4.2. MARKET VOLUME (UNITS)
14.6.4.3. AVERAGE SELLING PRICE (USD)
14.7 OTHERS
15 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY APPLICATION
15.1 OVERVIEW
15.2 LYSOSOMAL STORAGE DISEASES
15.2.1 GAUCHER'S DISEASE
15.2.2 FABRY DISEASE
15.2.3 POMPE DISEASE
15.2.4 HURLER - SCHEIE
15.2.5 SANFILIPO A
15.2.6 OTHERS
15.3 DIABETES
15.4 OBESITY
15.5 INHERITED METABOLIC DISORDERS
15.6 HYPERCHOLESTEROLEMIA
15.7 GALACTOSEMIA
15.8 MAPLE SYRUP URINE DISEASE (MSUD)
15.9 MEDIUM-CHAIN ACYL-COA DEHYDROGENASE (MCAD) DEFICIENCY
15.1 CONGENITAL ADRENAL HYPERPLASIA (CAH)
15.11 OTHER
16 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY THERAPY TYPE
16.1 OVERVIEW
16.2 MONOTHERAPY
16.3 COMBINATION THERAPY
17 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY DRUG TYPE
17.1 OVERVIEW
17.2 BRANDED
17.2.1 CEREZYME
17.2.2 VPRIV
17.2.3 REPLAGAL
17.2.4 GLIPIZIDE
17.2.5 ATORVASTATIN
17.2.6 CYSTAGON
17.2.7 LARONIDASE
17.2.8 ALDURAZYME
17.2.9 CYSTADANE
17.2.10 OTHER
17.3 GENERICS
18 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTARTION
18.1 OVERVIEW
18.2 ORAL
18.2.1 CAPSULE
18.2.2 TABLETS
18.2.3 OTHER
18.3 PARENTERAL
18.3.1 INTRAVENOUS
18.3.2 SUBCUTANEOUS
18.3.3 INTRAMUSCULAR
18.4 OTHER
19 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY PATIENT TYPE
19.1 OVERVIEW
19.2 PEDIATRIC
19.3 ADULT
19.3.1 MALE
19.3.2 FEMALE
19.4 GERIATRIC
19.4.1 MALE
19.4.2 FEMALE
20 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY END USER
20.1 OVERVIEW
20.2 HOSPITALS
20.2.1 PUBLIC
20.2.2 PRIVATE
20.3 SPECIALITY CLINICS
20.4 HOME CARE
20.5 AMBULATORY SURGICAL CENTERS
20.6 OTHERS
21 GLOBAL. METABOLIC DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
21.1 OVERVIEW
21.2 DIRECT TENDER
21.3 RETAIL PHARMACIES
21.3.1 HOSPITAL PHARMACIES
21.3.2 RETAIL PHARMACIES
21.3.3 ONLINE PHARMACIES
21.3.4 OTHER
21.4 OTHERS
22 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY REGION
GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
22.1 NORTH AMERICA
22.1.1 U.S.
22.1.2 CANADA
22.1.3 MEXICO
22.2 EUROPE
22.2.1 GERMANY
22.2.2 U.K.
22.2.3 ITALY
22.2.4 FRANCE
22.2.5 SPAIN
22.2.6 RUSSIA
22.2.7 SWITZERLAND
22.2.8 TURKEY
22.2.9 BELGIUM
22.2.10 NETHERLANDS
22.2.11 DENMARK
22.2.12 SWEDEN
22.2.13 POLAND
22.2.14 NORWAY
22.2.15 FINLAND
22.2.16 REST OF EUROPE
22.3 ASIA-PACIFIC
22.3.1 JAPAN
22.3.2 CHINA
22.3.3 SOUTH KOREA
22.3.4 INDIA
22.3.5 SINGAPORE
22.3.6 THAILAND
22.3.7 INDONESIA
22.3.8 MALAYSIA
22.3.9 PHILIPPINES
22.3.10 AUSTRALIA
22.3.11 NEW ZEALAND
22.3.12 VIETNAM
22.3.13 TAIWAN
22.3.14 REST OF ASIA-PACIFIC
22.4 SOUTH AMERICA
22.4.1 BRAZIL
22.4.2 ARGENTINA
22.4.3 REST OF SOUTH AMERICA
22.5 MIDDLE EAST AND AFRICA
22.5.1 SOUTH AFRICA
22.5.2 EGYPT
22.5.3 BAHRAIN
22.5.4 UNITED ARAB EMIRATES
22.5.5 KUWAIT
22.5.6 OMAN
22.5.7 QATAR
22.5.8 SAUDI ARABIA
22.5.9 REST OF MEA
22.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
23 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, SWOT AND DBMR ANALYSIS
24 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS: GLOBAL
24.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
24.3 COMPANY SHARE ANALYSIS: EUROPE
24.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
24.5 MERGERS & ACQUISITIONS
24.6 NEW PRODUCT DEVELOPMENT & APPROVALS
24.7 EXPANSIONS
24.8 REGULATORY CHANGES
24.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, COMPANY PROFILE
25.1 NOVO NORDISK A/S
25.1.1 COMPANY OVERVIEW
25.1.2 REVENUE ANALYSIS
25.1.3 GEOGRAPHIC PRESENCE
25.1.4 PRODUCT PORTFOLIO
25.1.5 RECENT DEVELOPMENTS
25.2 SANOFI S.A.(GENZYME)
25.2.1 COMPANY OVERVIEW
25.2.2 REVENUE ANALYSIS
25.2.3 GEOGRAPHIC PRESENCE
25.2.4 PRODUCT PORTFOLIO
25.2.5 RECENT DEVELOPMENTS
25.3 BOEHRINGER INGELHEIM GMB
25.3.1 COMPANY OVERVIEW
25.3.2 REVENUE ANALYSIS
25.3.3 GEOGRAPHIC PRESENCE
25.3.4 PRODUCT PORTFOLIO
25.3.5 RECENT DEVELOPMENTS
25.4 ELI LILLY AND COMPANY
25.4.1 COMPANY OVERVIEW
25.4.2 REVENUE ANALYSIS
25.4.3 GEOGRAPHIC PRESENCE
25.4.4 PRODUCT PORTFOLIO
25.4.5 RECENT DEVELOPMENTS
25.5 MERCK KGAA
25.5.1 COMPANY OVERVIEW
25.5.2 REVENUE ANALYSIS
25.5.3 GEOGRAPHIC PRESENCE
25.5.4 PRODUCT PORTFOLIO
25.5.5 RECENT DEVELOPMENTS
25.6 AMGEN, INC.
25.6.1 COMPANY OVERVIEW
25.6.2 REVENUE ANALYSIS
25.6.3 GEOGRAPHIC PRESENCE
25.6.4 PRODUCT PORTFOLIO
25.6.5 RECENT DEVELOPMENTS
25.7 ASTRAZENECA PLC
25.7.1 COMPANY OVERVIEW
25.7.2 REVENUE ANALYSIS
25.7.3 GEOGRAPHIC PRESENCE
25.7.4 PRODUCT PORTFOLIO
25.7.5 RECENT DEVELOPMENTS
25.8 ACTELION PHARMACEUTICALS LTD.
25.8.1 COMPANY OVERVIEW
25.8.2 REVENUE ANALYSIS
25.8.3 GEOGRAPHIC PRESENCE
25.8.4 PRODUCT PORTFOLIO
25.8.5 RECENT DEVELOPMENTS
25.9 SHIRE (TAKEDA PHARMACEUTICALS)
25.9.1 COMPANY OVERVIEW
25.9.2 REVENUE ANALYSIS
25.9.3 GEOGRAPHIC PRESENCE
25.9.4 PRODUCT PORTFOLIO
25.9.5 RECENT DEVELOPMENTS
25.1 ABBVIE, INC.
25.10.1 COMPANY OVERVIEW
25.10.2 REVENUE ANALYSIS
25.10.3 GEOGRAPHIC PRESENCE
25.10.4 PRODUCT PORTFOLIO
25.10.5 RECENT DEVELOPMENTS
25.11 BIOCON LTD.
25.11.1 COMPANY OVERVIEW
25.11.2 REVENUE ANALYSIS
25.11.3 GEOGRAPHIC PRESENCE
25.11.4 PRODUCT PORTFOLIO
25.11.5 RECENT DEVELOPMENTS
25.12 BIOMARIN PHARMACEUTICAL, INC.
25.12.1 COMPANY OVERVIEW
25.12.2 REVENUE ANALYSIS
25.12.3 GEOGRAPHIC PRESENCE
25.12.4 PRODUCT PORTFOLIO
25.12.5 RECENT DEVELOPMENTS
25.13 BRISTOL-MYERS SQUIBB COMPANY
25.13.1 COMPANY OVERVIEW
25.13.2 REVENUE ANALYSIS
25.13.3 GEOGRAPHIC PRESENCE
25.13.4 PRODUCT PORTFOLIO
25.13.5 RECENT DEVELOPMENTS
25.14 CIPLA, INC.
25.14.1 COMPANY OVERVIEW
25.14.2 REVENUE ANALYSIS
25.14.3 GEOGRAPHIC PRESENCE
25.14.4 PRODUCT PORTFOLIO
25.14.5 RECENT DEVELOPMENTS
25.15 CYMABAY THERAPEUTICS, INC.
25.15.1 COMPANY OVERVIEW
25.15.2 REVENUE ANALYSIS
25.15.3 GEOGRAPHIC PRESENCE
25.15.4 PRODUCT PORTFOLIO
25.15.5 RECENT DEVELOPMENTS
25.16 AMICUS THERAPEUTICS, INC.
25.16.1 COMPANY OVERVIEW
25.16.2 REVENUE ANALYSIS
25.16.3 GEOGRAPHIC PRESENCE
25.16.4 PRODUCT PORTFOLIO
25.16.5 RECENT DEVELOPMENTS
25.17 ULTRAGENYX PHARMACEUTICAL INC.
25.17.1 COMPANY OVERVIEW
25.17.2 REVENUE ANALYSIS
25.17.3 GEOGRAPHIC PRESENCE
25.17.4 PRODUCT PORTFOLIO
25.17.5 RECENT DEVELOPMENTS
25.18 REGENERON PHARMACEUTICALS INC.
25.18.1 COMPANY OVERVIEW
25.18.2 REVENUE ANALYSIS
25.18.3 GEOGRAPHIC PRESENCE
25.18.4 PRODUCT PORTFOLIO
25.18.5 RECENT DEVELOPMENTS
25.19 SANGAMO THERAPEUTICS
25.19.1 COMPANY OVERVIEW
25.19.2 REVENUE ANALYSIS
25.19.3 GEOGRAPHIC PRESENCE
25.19.4 PRODUCT PORTFOLIO
25.19.5 RECENT DEVELOPMENTS
25.2 ORCHARD THERAPEUTICS INC
25.20.1 COMPANY OVERVIEW
25.20.2 REVENUE ANALYSIS
25.20.3 GEOGRAPHIC PRESENCE
25.20.4 PRODUCT PORTFOLIO
25.20.5 RECENT DEVELOPMENTS
25.21 LEADIANT BIOSCIENCES, INC.
25.21.1 COMPANY OVERVIEW
25.21.2 REVENUE ANALYSIS
25.21.3 GEOGRAPHIC PRESENCE
25.21.4 PRODUCT PORTFOLIO
25.21.5 RECENT DEVELOPMENTS
25.22 UNIQURE N.V.
25.22.1 COMPANY OVERVIEW
25.22.2 REVENUE ANALYSIS
25.22.3 GEOGRAPHIC PRESENCE
25.22.4 PRODUCT PORTFOLIO
25.22.5 RECENT DEVELOPMENTS
25.23 BLUEBIRD BIO, INC.
25.23.1 COMPANY OVERVIEW
25.23.2 REVENUE ANALYSIS
25.23.3 GEOGRAPHIC PRESENCE
25.23.4 PRODUCT PORTFOLIO
25.23.5 RECENT DEVELOPMENTS
25.24 GENETHON
25.24.1 COMPANY OVERVIEW
25.24.2 REVENUE ANALYSIS
25.24.3 GEOGRAPHIC PRESENCE
25.24.4 PRODUCT PORTFOLIO
25.24.5 RECENT DEVELOPMENTS
25.25 AGTC
25.25.1 COMPANY OVERVIEW
25.25.2 REVENUE ANALYSIS
25.25.3 GEOGRAPHIC PRESENCE
25.25.4 PRODUCT PORTFOLIO
25.25.5 RECENT DEVELOPMENTS
*NoTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
26 RELATED REPORTS
27 CONCLUSION
28 QUESTIONNAIRE
29 ABOUT DATA BRIDGE MARKET RESEARCH
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.